Get the Stockscreener App
48.17
0.78%
0.325
Overview
News
Price History
Option Chain
Financials
Why BMY Down?
Discussions
Forecast
Stock Split
Dividend History
Bristol Myers Squibb Co stock is traded at $48.17, with a volume of 7.45M.
It is up +0.78% in the last 24 hours and down -3.93% over the past month.
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
See More
Previous Close:
$47.85
Open:
$47.87
24h Volume:
7.45M
Relative Volume:
0.53
Market Cap:
$98.12B
Revenue:
$47.64B
Net Income/Loss:
$5.42B
P/E Ratio:
18.04
EPS:
2.67
Net Cash Flow:
$13.09B
1W Performance:
+2.93%
1M Performance:
-3.93%
6M Performance:
-18.57%
1Y Performance:
+19.81%
1-Day Range:
$47.30
$48.30
1-Week Range:
$46.10
$48.30
52-Week Range:
$39.35
$63.33
Bristol Myers Squibb Co Stock (BMY) Company Profile
Name
Bristol Myers Squibb Co
Sector
Industry
Phone
(609) 252-4621
Address
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
48.22 | 95.71B | 47.64B | 5.42B | 13.09B | 2.67 |
|
LLY
Lilly Eli Co
|
743.84 | 642.06B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
155.39 | 367.19B | 89.33B | 21.81B | 18.57B | 8.99 |
|
ABBV
Abbvie Inc
|
186.36 | 322.44B | 57.37B | 4.20B | 15.39B | 2.35 |
|
NVS
Novartis Ag Adr
|
115.61 | 222.20B | 53.22B | 12.86B | 14.85B | 6.39 |
|
NVO
Novo Nordisk Adr
|
71.42 | 302.90B | 43.59B | 15.04B | 10.74B | 3.3766 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Apr-22-25 | Initiated | Piper Sandler | Overweight |
| Dec-16-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Nov-12-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-25-24 | Downgrade | Citigroup | Buy → Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jul-29-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-11-24 | Downgrade | Societe Generale | Buy → Hold |
| Feb-06-24 | Downgrade | Redburn Atlantic | Buy → Neutral |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-15-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-27-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Oct-27-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Oct-27-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jul-10-23 | Initiated | SVB Securities | Market Perform |
| Jun-28-23 | Initiated | Daiwa Securities | Outperform |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Jan-17-23 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-18-22 | Initiated | Credit Suisse | Neutral |
| Oct-10-22 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-14-22 | Downgrade | Berenberg | Buy → Hold |
| Jun-03-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Underweight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Nov-01-21 | Downgrade | Argus | Buy → Hold |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-30-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-13-21 | Upgrade | Truist | Hold → Buy |
| Nov-16-20 | Upgrade | Societe Generale | Hold → Buy |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Nov-06-20 | Downgrade | Gabelli & Co | Buy → Hold |
| Oct-19-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Jul-28-20 | Initiated | Raymond James | Outperform |
| Apr-02-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-06-20 | Resumed | Citigroup | Buy |
| Dec-13-19 | Upgrade | Argus | Hold → Buy |
| Nov-22-19 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Aug-14-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| May-28-19 | Initiated | Goldman | Buy |
| May-20-19 | Downgrade | Argus | Buy → Hold |
| May-03-19 | Upgrade | Barclays | Equal Weight → Overweight |
| May-03-19 | Resumed | JP Morgan | Overweight |
| Jan-15-19 | Upgrade | Societe Generale | Sell → Buy |
| Oct-22-18 | Downgrade | Citigroup | Buy → Neutral |
View All
Bristol Myers Squibb Co Stock (BMY) Latest News
BMO maintains Bristol-Myers Squibb stock at Market Perform By Investing.com - Investing.com India
BMO maintains Bristol-Myers Squibb stock at Market Perform - Investing.com
Another Bristol Myers exec goes to Acadia; David Southwell takes CEO job at ARCH-backed cancer biotech - Endpoints News
Bispecific Antibody Drug Conjugates Clinical Trials Bispecific ADC Market Size Insight - GlobeNewswire Inc.
BMY's Opdivo SC Gets EU Nod for Multiple Solid Tumor Indications - TradingView
EC approval for BMS’ subcutaneous Opdivo - The Pharma Letter
Bristol Myers Loses 20.7% in 3 Months: Buy, Sell or Hold the Stock? - Yahoo Finance
EC approves BMS’ nivolumab SC formulation for solid tumours - Yahoo Finance
Bristol Myers Squibb bags European Commission nod for Subcutaneous formulation of Opdivo across multiple... - Medical Dialogues
Bristol-Myers Squibb at Bernstein Conference: Strategic Growth and Innovation - Investing.com
BMS says subcutaneous version of Opdivo gets EU nod - FirstWord Pharma
Bristol Myers Squibb (BMY) Upgraded to Buy Amid Improved Dividend Prospects - GuruFocus
Bristol Myers Squibb Receives European Commission Approval for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications - BioSpace
Targeted Drug Delivery Research Business Analysis Report 2024-2030 with Focus on 30+ Key Players Such as AbbVie, Amgen, AstraZeneca, Becton Dickinson and Co, & Bristol-Myers Squibb - GlobeNewswire
BMY Gains European Approval for New Opdivo Formulation | BMY Stock News - GuruFocus
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications | HALO Stock News - GuruFocus
Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications - marketscreener.com
Bristol Myers: EU green light for Opdivo subcutaneous injection - marketscreener.com
Bristol Myers (BMY) Gains European Approval for New Opdivo Formulation | BMY Stock News - GuruFocus
Bristol Myers Squibb Receives European Commission Approval for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications | BMY Stock News - GuruFocus
Bristol Myers Squibb to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference - Yahoo Finance
Bristol-Myers Squibb: This Undervalued Dog Needs An Option Collar (NYSE:BMY) - Seeking Alpha
Bristol-Myers: Among The Cheapest Pharma Names, Now Yielding Above 5% (NYSE:BMY) - Seeking Alpha
Bristol Myers Squibb’s SWOT analysis: stock faces challenges amid promising pipeline - Investing.com
Deutsche Bank Accelerates Digital Transformation with IBM's Software Portfolio - The Globe and Mail
Bristol Myers Squibb (BMY) is a Top-Ranked Value Stock: Should You Buy? - Yahoo Finance
Bristol-Myers Squibb (NYSE:BMY) Showcases Breakthrough Oncology Data at ASCO 2025 Meeting - simplywall.st
Bristol Myers Squibb to Present Data at ASCO® 2025 Highlighting Differentiated Research Platform of Oncology Treatments and Innovative Research Pipeline - Yahoo Finance
Celgene Appeals Pennsylvania Tax After Bristol-Myers Acquisition - news.bloombergtax.com
Areas of interest - Bristol Myers Squibb
Bristol Myers, Novartis Take Drug Rebate Lawsuits to DC Circuit - Bloomberg Law News
Tubulis achieves key milestone in BMS deal - The Pharma Letter
Bristol Myers Squibb patents new BCL-6 degradation inducers - BioWorld MedTech
Here's How You Can Earn $100 In Passive Income By Investing In Bristol-Myers Squibb Stock - Yahoo Finance
Bristol Myers Squibb patents new USP1 inhibitors - BioWorld MedTech
Bristol Myers Promises $40 Billion US Investment Over Five Years - MSN
Bristol Myers Squibb (BMY) Gains EU Nod for Opdivo in Lung Cance - GuruFocus
Bristol Myers Squibb (BMY) Gains EU Nod for Opdivo in Lung Cancer Treatment - GuruFocus
Bristol Myers (BMY) Faces Market Movement Amid Medicare Part B & D Draft Guidance | BMY Stock News - GuruFocus
Bristol-Myers Curbs Investor $6.4 Billion Payout Suit on Appeal - Bloomberg Law News
Jim Cramer On Bristol-Myers Squibb: “Waiting For It To Bottom” - Insider Monkey
BMY Gains EU Approval for Expanded Use of Opdivo in Lung Cancer Treatment | BMY Stock News - GuruFocus
Reclaiming our time: Eightfold’s founder on the promise of agentic AI - HR Executive
BMY Secures EC Approval for Opdivo Regimen in Lung Cancer Treatm - GuruFocus
Jim Cramer On Bristol-Myers Squibb: "Waiting For It To Bottom" - Yahoo Finance
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MSN
Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know - MSN
Bristol Myers Squibb (BMY) CEO Calls for Fair Global Drug Pricin - GuruFocus
Bristol Myers Squibb announces $40bn US investment plan over five years - MSN
'You Have to Punch the Bully in the Nose': Newly Retired Bristol Myers Squibb GC Calls Law Firms That Settled With Trump Naive - Law.com
Bristol Myers Squibb Co Stock (BMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.21%
0.93%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):